Tofacitinib improves composite endpoint measures of disease in patients with psoriatic arthritis

פריטים דומים

• Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease
  מאת: Helliwell, P, et al.
  יצא לאור: (2018)
• Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
  מאת: Nash, P, et al.
  יצא לאור: (2018)
• Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
  מאת: Coates, L, et al.
  יצא לאור: (2021)
• Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study
  מאת: Nash, P, et al.
  יצא לאור: (2018)
• Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study
  מאת: Nash, P, et al.
  יצא לאור: (2018)